Veru Inc (VERU) Receives a Buy from Maxim Group


Maxim Group analyst Jason McCarthy maintained a Buy rating on Veru Inc (VERU) today and set a price target of $6. The company’s shares opened today at $1.51.

McCarthy wrote:

“Veru reported F1Q19 (FYE Sept) with revenue of $6.4M, derived from its FC2 business and a net loss of ($2.1M), ending the period with $9M in cash. VERU-111’s open-label Phase 1b/2 in prostate cancer is enrolling, data expected in 2019. A Phase 2 trial of zuclomiphene citrate is enrolling, data expected mid-2019. TADFIN tablet for benign prostatic hyperplasia NDA remains on track for submission in 2019, with potential approval in 2020.”

According to TipRanks.com, McCarthy ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -4.0% and a 33.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Aridis Pharmaceuticals Inc, and Adial Pharmaceuticals Inc.

Currently, the analyst consensus on Veru Inc is a Strong Buy with an average price target of $6.83.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.37 and a one-year low of $1.20. Currently, Veru Inc has an average volume of 90.87K.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERU in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Veru, Inc. is a urology and oncology biopharmaceutical company, which engages in the development, manufacture and marketing of consumer health care products. It operates through the Commercial; and Research and Development segments.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts